Approximately 5% of patients with D’Amico intermediate- to high-risk, hormone-sensitive prostate cancer (PCa) have a tumour that lacks prostate-specific membrane antigen(PSMA) expression on preoperative positron emission tomography (PET)/CT (non-PSMAPET-expressing PCa). Our recent study showed that patients with non-PSMAPET-expressing PCa had similar clinical, pathological, and immunohistochemical characteristics to patients with PSMAPET-expressing tumours, suggesting that these patients may have similar prognostic features. In the present study, oncological outcomes of patients with non-PSMAPET-expressing PCa were studied. In conclusion, after RARP, patients with a ‘negative-for-PCa’ preoperative PSMA PET/CT had similar BCR-free survival to patients with PSMAPET-expressing PCa. A restaging PSMAPET/CT seems to be valuable in the detection of recurrences in patients with non-PSMAPET-expressing PCa who developed BCR.
